Latest Breaking News On - Biohaven pharmaceutical holding - Page 1 : comparemela.com

The company on Wednesday forecast revenue from its COVID-19 vaccine and treatment to be $8 billion in 2024, a far cry from the $57 billion in 2022. In March, Pfizer announced a $43 billion acquisition of drugmaker Seagen to bring into its fold four approved cancer therapies. Last year, the company struck an $11.6 billion deal for migraine drug maker Biohaven Pharmaceutical Holding and bought Global Blood Therapeutics for $5.4 billion, adding sickle cell disease treatment Oxbryta to its pipeline.

United statesKhushi mandowaraSriraj kalluvilaManas mishraDamien conoverCaribou sciencesBiohaven pharmaceutical holdingGlobal blood therapeuticsAkero therapeuticsUnited kingdomGlobal blood therapeuticsBiohaven pharmaceutical holdingBiohaven pharmaceuticalCost cuttingAribou sciences and akero therapeutics